Orion invites analysts and media to Q1 news conference on Wednesday 27 April 2011



Orion will publish its Interim Report January-March 2011 on Wednesday, 27 April 2011 approximately at 12:00 Finnish time (EEST). The release and related presentation material in Finnish and in English will be available on the Group's homepage at www.orion.fi/en promptly after the publishing.


News conference for analysts and media on Wednesday 27 April 2011 at 13:30 EEST

A news conference for analysts and media will be held on Wednesday 27 April 2011 at 13:30 EEST at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki. President and CEO Timo Lappalainen will give a brief presentation in English on the financial review.


Live webcast and conference call

The event can be followed live as a webcast accessible at www.orion.fi/en. Questions can be asked also through conference call lines after the result presentation.


The conference call ID is 891283 and the phone numbers to participate the conference are:
when calling from the United States +1 866 803 8344
when calling from other countries +44 (0)20 7162 0125


News conference recordings

A recording of the event in English will be available later the same day via a link on the Orion website. A recording of the presentation by the President and CEO in Finnish will be available on the Orion website later the same day.


Silent period

The silent period preceding the publication is ongoing and continues until the disclosure.




Orion Corporation




Timo Lappalainen
President and CEO
Jari Karlson



Orion Corporation


Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.


The Group's net sales in 2010 amounted to approximately EUR 850 million. The Company invested EUR 85 million in research and development. At the end of 2010, the Group had a total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650 in other European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.